Docosahexaenoic Acid Intake and Health in Adults and Older Adults: A Narrative Review of Disparities by Country Income Level

Why It Matters

Understanding DHA’s health impact and the income‑related disparities informs global nutrition policies and highlights the need for more research in lower‑income settings where deficiency may exacerbate disease risk.

Key Takeaways

• Most DHA studies originate from high‑income nations.
• Higher DHA linked to lower ischemic stroke risk in women.
• Biomarker studies show DHA improves lipid particle size.
• Upper‑middle‑income populations exhibit lower DHA status.
• Evidence for DHA’s cognitive benefits remains mixed.

Pulse Analysis

Docosahexaenoic acid, the long‑chain omega‑3 fatty acid most abundant in marine fish, remains a cornerstone of dietary recommendations for heart and brain health. Yet global consumption is far from uniform; high‑income nations typically achieve higher intakes through regular seafood consumption and fortified supplements, while many upper‑middle‑income regions report markedly lower blood DHA concentrations. This disparity reflects differences in food availability, cultural dietary patterns, and economic access to omega‑3‑rich foods, underscoring a broader nutrition equity challenge that policymakers must address.

The cardiovascular literature compiled in the review paints a nuanced picture. Cohort analyses consistently associate higher plasma or erythrocyte DHA with reduced risk of ischemic stroke, particularly among women, and with more favorable lipid particle distributions such as larger LDL and HDL particles. However, randomized trials and some large prospective studies reveal modest or null effects on blood pressure, weight change, and overall mortality. These mixed findings suggest that DHA’s benefits may be context‑dependent, influenced by baseline status, dosage, and concurrent risk factors, and that biomarker‑driven assessments could better target individuals most likely to profit.

Beyond the heart, DHA’s role in cognition and mental health continues to generate debate. Observational data link higher DHA levels to lower incidence of Alzheimer’s disease and better memory performance, yet intervention trials often produce heterogeneous outcomes, possibly due to variations in study design, dosage, and participant baseline DHA. The review’s emphasis on income‑related gaps highlights an urgent need for rigorous trials in lower‑income settings, where DHA deficiency may amplify neurodegenerative risk. Aligning research priorities with these disparities can guide more equitable nutrition guidelines and inform fortification or supplementation strategies worldwide.